Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
about
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosisChronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages.Associations between Flavonoid Intakes and Gut Microbiota in a Group of Adults with Cystic Fibrosis
P2860
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@ast
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@en
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@en-gb
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@nl
type
label
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@ast
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@en
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@en-gb
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@nl
prefLabel
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@ast
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@en
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@en-gb
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@nl
P2093
P2860
P1476
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
@en
P2093
Ian P Sinha
Kerry Dwan
Kevin W Southern
Michael Schechter
Sanjay Patel
P2860
P304
P356
10.1002/14651858.CD009841.PUB2
P577
2015-03-26T00:00:00Z